Cardano взлетел на 20% — что происходит?
Криптовалюта Cardano (ADA) подскочила во вторник на 20% после анонса о грядущем листинге на криптобирже Coinbase.
ADA заняла четвертое место в рейтинге криптовалют по капитализации.
В феврале Cardano вырос почти на 300%. В среду ADA обновил максимумы предыдущего дня, достигнув $1,26, однако всё еще ниже исторического максимума в $1,45, зафиксированного 27 февраля.
Coinbase уже начала принимать входящие переводы в ADA и откроет торги 18 марта при условии соблюдения требований к ликвидности. Криптовалюта добавляется на платформу профессионального трейдинга Coinbase Pro, пишет ttrcoin.
На розничном портале Coinbase.com и в мобильном приложении ADA пока купить будет нельзя.
На прошлой неделе Bloomberg добавил ADA в свой терминал. По имеющимся сведениям, было добавлено только описание криптовалюты без возможности отслеживания ее курса. В воскресенье Bloomberg также опубликовал статью об успехах Cardano на рынке.
Международная онлайн-платформа «Спросите доктора» (Ask The Doctor) и ее токен AskToken переезжают с блокчейна Ethereum на Cardano, пишет beincrypto. Причиной миграции из экосистемы Ethereum является непомерно высокая стоимость транзакций на ETH.
Платформа Ask The Doctor позволяет пользователям зарабатывать криптовалюту в процессе изучения базовых основ в сфере охраны здоровья и медицинской помощи. В дальнейшем они могут тратить заработанное на оплату медицинских услуг и лечения.
Между тем, CEO Galaxy Digital Майк Новограц усомнился в полезности Cardano: «Может кто-нибудь описать настоящий бычий сценарий для ADA? Кто-то использует его? Почему такая большая капитализация? Это одна из немногих криптовалют, которыми я не торговал в своей жизни».
Клиентам FxPro доступен бесплатный теханализ и рекомендации от Trading Central.
Аналитика FxTeam в Telegram – читайте новости и аналитику первыми!
Management of Hyperglycemia in Type 2 Diabetes: ADA-EASD Consensus Report 2022
The ADA and the EASD have launched their new consensus update on management of hyperglycemia in type 2 diabetes. The update has been prepared by an international committee of experts that include John B. Buse, MD, PhD, (University of North Carolina School of Medicine, Chapel Hill, NC); Melanie J. Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSciat (Leicester Diabetes Centre, Leicester, UK); and their colleagues. It updates the previous 2018 and 2019 consensus reports, and like its predecessors, this new document has been co-published in the ADA journal Diabetes Care ® and EASD’s journal Diabetologia.
This slide deck was presented at the 58th EASD Annual Meeting on September 23, 2022.
View the consensus report.
Ada 2021 что ждать
Open GPT Console
Open Oracle Keywords
center of excellence
Download from app store
You are using an unsupported browser. As of January 12, 2016, Microsoft will only support the most current version of Internet Explorer available (More information available on microsoft.com), and PracticeUpdate has followed suit. Please upgrade your browser to improve your experience.
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Live Updates
Panel reviews professional competencies for implementing diabetes technology into clinical practice
Seven newly defined domains of diabetes technology competencies aim to empower diabetes care and education specialists to expand the horizon of innovative diabetes education, management, and support at all practice levels. Shivajirao P. Patil, MD, MPH, BC-ADM, FAAFP, and other members of the team that developed the competencies explained the rationale and methodology behind them. Read more
Session Coverage
September 5, 2023
Sex affects metabolism and glucose homeostasis through multiple mechanisms
Of the three factors that affect sex-based differences in metabolism, panelist Yong Xu, MD, PhD, said the most obvious is gonadal hormones, testosterone and estradiol, and their receptor signaling. The most fundamental factor is sex-linked chromosomes, and the most ignored is autosomal genes, he explained. Read more
Session Coverage
September 5, 2023
Studies examine impact of meal timing, exercise, and circadian rhythm on metabolic health
Research with humans, other primates, and fruit flies has revealed new understanding of how when food is consumed and other factors affect metabolism. Early time-restricted feeding may be a strategy for the improvement of cardiovascular risk in older populations, Kylie Kavanagh, DVM, MS, MPH, reported. Read more
Session Coverage
August 29, 2023
International panel discusses type 1 diabetes screening studies and public health initiatives
Experts from Germany, Finland, and the U.S. discussed the benefits of early diagnosis of type 1 diabetes. Anette-Gabriele Ziegler, MD, explained that about 80% of children and adolescents who develop the disease by age 15 develop antibodies within the first six years of life, making screening at age 6 particularly efficient for diagnosis. Read more
Session Coverage
August 29, 2023
Symposium examines cardiovascular health during pregnancy and beyond
Growing recognition of the impact of hypertension on maternal and fetal outcomes has helped drive recent changes to lower treatment targets for the condition during pregnancy. Kartik K. Venkatesh, MD, PhD, discussed the latest updates in hypertension in pregnancy. The dynamics of hypertriglyceridemia and pregnancy, and breastfeeding and cardiometabolic health also were discussed. Read more
Session Coverage
August 29, 2023
Experts analyze data to combat diabetes-related retinal disease
Diabetes-related retinal disease is prevalent in adults with diabetes and the most common cause of blindness in working-age adults. Current therapies target interventions during the late stages of retinal disease, when vision is already dramatically compromised. Jennifer Sun, MD, MPH, Stela Vujosevic, MD, PhD, and Patrice E. Fort, MS, PhD, discussed potential solutions for patients to preserve vision and prevent retinal disease progression. Read more
Session Coverage
August 22, 2023
ADA/AACC Symposium reviews tools for measuring glycemia in the hospital ahead of new recommendations for analysis
How best to measure and control glycemia in the hospital remains unclear. Continuous glucose monitoring is one option, and hospitals use readings from these devices to adjust insulin doses and prevent hypoglycemia. However, labs are more accurate than glucose meters, said panelist David B. Sacks, MB, ChB. Read more
Session Coverage
August 22, 2023
Panelists discuss ongoing progress toward precision medicine in diabetes
The promise of treatment informed by patient genetics continues to grow for people living with monogenic diabetes, type 1 diabetes, type 2 diabetes, and gestational diabetes. One ongoing barrier in the U.S. is lack of insurance coverage for genetic testing, said Rochelle N. Naylor, MD, part of a panel on the international Precision Medicine in Diabetes Initiative. Read more
Session Coverage
August 22, 2023
Design and engineering can inform diabetes quality teams
Designers and engineers play a role in the effectiveness and usability of diabetes technology, and three experts, including Wendy Rogers, PhD, gathered for a panel discussion about quality teams and what they can learn from design and engineering processes. Dr. Rogers outlined a framework for designing technology that supports patients from diagnosis to sustained self-care. Read more
Presenter Profiles
August 22, 2023
ICYMI Presenter Profile: Do-It-Yourself (DIY) vs. Commercial Closed-Loop Systems for Managing Type 1 Diabetes
Dana M. Lewis gives an overview of a Professional Interest Group discussion held at the 83rd Scientific Sessions. She helped develop the first open-source automated insulin delivery system. Read more
Presenter Profiles
August 22, 2023
ICYMI Presenter Profile: What Is the Best Approach to the Management of Painful Diabetic Neuropathy?
Lance M. McCracken, PhD, who studies stress responses and blood glucose in diabetes, previews a Professional Interest Group discussion held at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28. Read more
Session Coverage
August 15, 2023
Investigators share new findings in islet cell interactions
Pancreatic islets contain five endocrine cell types that interact with each other and the rest of the body. Scientists shared their latest research into the islet-cell interactome during the 83rd Scientific Sessions. Maria L. Golson, PhD, explored the mechanisms by which delta cells regulate beta cell function. Delta cells are known primarily for their production of somatostatin, but they are also highly enriched for leptin compared to beta cells.
Session Coverage
August 15, 2023
Experts debate role of the microbiome in obesity
The microbiome accounts for 99% of the genes in a human, yet the notion that the microbiome plays a role in human obesity is all hype, according to Max Nieuwdorp, MD, PhD. He debated Rob Knight, PhD, on this issue. Dr. Knight supported the argument that the microbiome is key in obesity. Read more
Session Coverage
August 15, 2023
Symposium compares models for unlocking the mechanisms of obesity
James D. Johnson, PhD, and Kevin D. Hall, PhD, discussed the scientific merit of and the hypotheses driving the two leading models for understanding obesity: the carbohydrate-insulin model and the energy-balance model. Read more
Presenter Profiles
August 15, 2023
ICYMI Presenter Profile: Updates in Diabetes and Fasting
Mohamed M. Hassanein, FRCP, CCST UK, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28. Read more
Session Coverage
August 8, 2023
Researchers investigate physical activity considerations for older adults with diabetes
A panel of experts analyzed the effects of physical activity on older adults with diabetes to determine potential therapeutic interventions. Bruce A. Perkins, MD, MPH, discussed his research into longevity in type 1 diabetes and the benefits physical activity has on beta-cell reserve.
Session Coverage
August 8, 2023
Session examines how to reduce hypoglycemia at patient and system levels
In the U.S. alone, the direct cost of hospitalization for severe hypoglycemia tops $1.8 billion, reported Alexandria Ratzki-Leewing, PhD, in a session that offered a detailed look at the challenges hypoglycemia causes for older people living with diabetes, including health outcomes and financial burdens. Read more
Session Coverage
August 8, 2023
Speakers analyze strategies to improve type 2 diabetes outcomes for adolescents
Following the COVID-19 pandemic, researchers observed an increase in type 2 diabetes among adolescents. Experts, including Katie O’Sullivan, MD, presented three strategies to help address the disease in youths: mobilize an interdisciplinary team, explore medical or surgical treatments, and provide community intervention programs. Read more
Presenter Profiles
August 8, 2023
ICYMI Presenter Profile: Joint ADA/ISPAD Symposium—Why Aren’t All Guidelines the Same? A Focused Review of Recommendations from ISPAD 2022 and ADA 2023
Priya Prahalad, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28. Read more
Session Coverage
August 1, 2023
ADA and partners develop consensus statement on person-reported outcomes
A forthcoming consensus statement on PROs looks beyond numbers associated with diabetes—glucose levels, A1C, time in range—to the myriad ways the disease affects daily life. Because diabetes relies on the patient’s own engagement in therapeutic behaviors, integrating PROs into clinical models for care is crucial, explained the authors, including Jennifer L. Sherr, MD, PhD.
Session Coverage
August 1, 2023
Physicians debate the comparative benefits of smart insulin delivery and pancreatic cell transplant
The debate continues over using beta-cell replacement or automated insulin delivery in the treatment of patients with type 1 diabetes. Michael R. Rickels, MD, MS, presented support for the biological solution provided by islet transplantation, while Bruce A. Buckingham, MD, presented data supporting the artificial pancreas. Read more
Session Coverage
August 1, 2023
Experts discuss the physiology of exercise and clinical management of athletes with type 1 diabetes
Michael Riddell, PhD, and Lori M. Laffel, MD, MPH, provided insight into the unique needs of athletes—children and adults—who live with type 1 diabetes. Different forms of exercise affect glycemia differently, making it important for the type, duration, and intensity of exercise to be factored into the athlete’s care plan. Read more
Presenter Profiles
August 1, 2023
ICYMI Presenter Profile: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
Filip K. Knop, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28. Read more
Session Coverage
July 25, 2023
Time in range becomes an increasingly important diabetes target
A1C has long been the gold standard for assessing glycemic control in diabetes over time, but continuous glucose monitoring (CGM) metrics such as time in range (TIR) are increasingly becoming popular because they represent real-time results. Revital Nimri, MD, and other experts discussed the role of TIR and other CGM metrics that use the most updated data to provide insight into helping reduce long-term diabetes complications.
Session Coverage
July 25, 2023
Panelists look at impact of SGLT2 inhibitors, GLP-1 receptor agonists in CVD and diabetes
Growing evidence indicates SGLT2 inhibitors and GLP-1 receptor agonists have beneficial effects not only in patients with type 2 diabetes but also those at risk for cardiovascular disease. Physicians and scientists, including Darren K. McGuire, MD, MHSc, presented findings from trials that demonstrate positive clinical outcomes. Read more
Session Coverage
July 25, 2023
Symposium examines type 1 diabetes in other settings such as cancer immunotherapy and celiac disease
Cancer immunotherapy, monogenic primary immune deficiencies, and celiac disease may have pathologic links to type 1 diabetes. Four experts, including Arabella Young, PhD, discussed ways these conditions may be linked, and in some cases how they can be screened for together. Read more
Session Coverage
July 25, 2023
Session offers in-clinic tips for obtaining, interpreting diabetes device data
More than 3 million Americans use continuous glucose monitoring, which provides a plethora of useful data for clinicians. Obtaining and interpreting that data continues to present challenges. Rebecca Rick Longo, MSN, ACNP-BC, CDCES, offered solutions for efficiently downloading the data, and Cari Berget, MPH, RN, CDCES, explained a three-step process for reviewing and using the data to support clinical decision-making. Read more
Presenter Profiles
July 25, 2023
ICYMI Presenter Profile: Discussion on Diabetes Self-Management Education and Support (DSMES)
Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, APh, previews a Professional Interest Group discussion held at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28. Read more
Session Coverage
July 18, 2023
Panel explores evolving impact of teplizumab on type 1 diabetes trials, treatment
Teplizumab became the first FDA-approved drug for the delay and prevention of type 1 diabetes, but it also comes with its own challenges. Presenters, including Kevan C. Herold, MD, shared the benefits of teplizumab along with some of the barriers faced for the research community, clinical practice, and patients.
Session Coverage
July 18, 2023
DCCT/EDIC proves to be the most impactful research in diabetes history
Before DCCT/EDIC, most individuals with type 1 diabetes died in their late 40s. Four decades later, David M. Nathan, MD, Chair of the DCCT/EDIC Research Group, and other investigators explained how management of the disease has been transformed by the data gleaned from this groundbreaking research and, as a result, lifespans have been extended. Read more
Session Coverage
July 18, 2023
Global health experts discuss how inequity fuels international diabetes trends
New statistics indicate that more than 1.31 billion people across the globe could be living with diabetes in the next 30 years. In a special symposium on how inequity contributes to the significant growth in this population, Louise J. Maple-Brown, MBBS, FRACP, PhD, and Sian Graham, BAppSc, discussed how select social determinants of health impact diabetes outcomes. Read more
Session Coverage
July 18, 2023
Debate weighs the efficacy of initial combination therapy for type 2 diabetes
Ralph A. DeFronzo, MD, and David M. Nathan, MD, debated whether combination therapy or sequential therapy is the most effective regimen for treating type 2 diabetes. Dr. DeFronzo advocated for combination therapy for its ability to efficiently correct multiple pathophysiologic defects. Dr. Nathan countered that sequential therapy is a more verifiable and efficient initial approach to disease management. Read more
July 18, 2023
Presenter Profile: Discussion on Women’s Interprofessional Network of the ADA (WIN ADA)—Amplifying Women’s Voices in the Diabetes Workforce—A Panel Discussion
Sue-Ellen Anderson-Haynes, MS, RDN, CDCES, LDN, CPT, previews a panel discussion held at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28.
Session Coverage
July 11, 2023
SURMOUNT-2 shows weight loss, A1C reduction in participants with type 2 diabetes
In the SURMOUNT-2 trial, individuals with obesity and type 2 diabetes had a more than 15% reduction in weight and an almost 6% reduction in A1C while taking the dual incretin inhibitor tirzepatide. Researchers, including W. Timothy Garvey, MD, MACE, the trial’s principal investigator, discussed how a weight-focused approach can help treat obesity and type 2 diabetes.
Session Coverage
July 11, 2023
Positive results in COORDINATE-Diabetes show prescribing habits can be changed
The COORDINATE-Diabetes trial studied the impact of a multifaceted educational intervention for clinical staff on prescription rates for three groups of therapies used to treat type 2 diabetes and cardiovascular disease. “COORDINATE shows that it is possible to change prescribing behavior using a process that is not resource intensive,” said Principal Investigator Christopher B. Granger, MD, FACC, FAHA. Read more
Session Coverage
July 11, 2023
Phase 2 trial results demonstrate benefits of retatrutide in obesity, type 2 diabetes, NASH
Researchers presented results from their studies of the effects of retatrutide on obesity, type 2 diabetes, and nonalcoholic steatohepatitis. “The most interesting reason to pursue glucagon agonism in a multi-receptor agonist is the possibility that you could alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia,” said David A. D’Alessio, MD. Read more
Session Coverage
July 11, 2023
Investigators present findings from OASIS and PIONEER oral semaglutide trials
A panel of investigators shared conclusions from two clinical trials studying the efficacy of oral semaglutide in treating diabetes and obesity. “The availability of an oral GLP-1 with weight-lowering efficacy could potentially give people requiring treatment for obesity and their physicians a great option for choice of treatment,” said Julio Rosenstock, MD. Read more
Session Coverage
July 11, 2023
Metabolic surgery superior to medical and lifestyle interventions to manage type 2 diabetes long term
ARMMS-T2D showed gastric bypass, sleeve gastrectomy, and adjustable gastric band surgeries to be more effective than intensive medical and lifestyle management for individuals with type 2 diabetes. Anita Courcoulas, MD, MPH, shared results from the prospective, observational follow-up to four trials comparing surgery and medical management. Read more
Session Coverage
July 11, 2023
Panelists address current controversies in the primary prevention of macrovascular complications for diabetes patients
Experts including cardiologist Heather M. Johnson, MD, MS, MMM, analyzed the association of hyperlipidemia, hypertension, and glucose levels with macrovascular risk at the 83rd Scientific Sessions. Their discussion focused on a case study of a patient with diabetes and hypertension to determine the best treatment to manage both. Read more
Session Coverage
June 26, 2023
Outstanding Scientific Achievement Award winner furthers understanding of the ailing beta-cell in diabetes
Carmella Evans-Molina, MD, PhD, this year’s Outstanding Scientific Achievement Award winner, was first interested in understanding the beta-cell pathways that drive the transition from normoglycemia to dysglycemia to diabetes. Now she is focusing on ways to leverage beta-cell stress to inform type 1 diabetes biomarker development.
Session Coverage
June 26, 2023
Studies indicate differences in diabetic kidney disease in type 1 and type 2 diabetes
DKD may look the same clinically in type 1 diabetes and type 2 diabetes, but research suggests there are differences that could influence risk, progression, and treatment for patients with each type of diabetes. “We are looking into molecular pathways and planning direct comparisons between type 1 diabetes and type 2 diabetes to find altered mechanisms,” said Viji Nair, PhD, MS. Read more
Session Coverage
June 26, 2023
Presenters review social determinants of health and their impact on diabetes
Factors including food insecurity, community, and economic disadvantage play integral roles in the development and care of diabetes, according to four experts who took a closer look at social determinants of health and diabetes. Felicia Hill-Briggs, PhD, ABPP, provided an overview of SDOH in the development of diabetes. She was the chair of the committee that wrote the scientific review of SDOH for Diabetes Care. Read more
Session Coverage
June 26, 2023
Four experts outline game-changing nutrient-stimulated hormone anti-obesity therapies
Nutrient-stimulated hormones have changed the landscape of weight loss recently, and four scientists, including Jonathan Campbell, PhD, presented information about several types of combinations of these therapies that have and are being tested in trials. Read more
Session Coverage
June 26, 2023
Researchers highlight major discoveries in Year in Review
In a Monday morning symposium, three scientists spotlighted major advancements in diabetes from the past year, from new guidelines and statements to a bionic pancreas and anti-obesity drugs. John B. Buse, MD, PhD, reported that health equity issues remain the biggest challenge in advancing diabetes treatment and prevention. Read more
Session Coverage
June 26, 2023
Hot topics in nutrition include food as medicine, binge-eating disorder, and weight stigma
Nutrition plays a significant role in a patient’s diabetes management, but there is no universal approach to incorporating a healthy diet. Ka Hei Karen Lau, MS, RDN, LDN, CDCES, and other specialists explored various nutrition programs, such as providing food benefits to those without access to food, offering education on food choices, and addressing weight stigma. Read more
June 26, 2023
Upcoming presentation: Comparing Beta-Cell Replacement vs. Artificial Pancreas—Smart Insulins with a Focus on New Innovations—Untested Technologies
Presenter Michael R. Rickels, MD, MS, shares insight into a debate that begins Monday at 3:15 p.m. PT in Room 30. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Starting soon: Beyond Antihyperglycemic and Antihypertensive Agents for Diabetic Kidney Disease
A symposium beginning Monday at 3:15 p.m. PT in Room 28 will feature panel of diabetes care experts, including Christine Limonte, MD, discussing what is happening in the world of antihyperglycemic and antihypertensive agents—and beyond—as diabetic kidney disease continues to be a prevalent complication from diabetes. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
#ADA2023 Live Coverage
June 26, 2023
‘What drives you?’ There’s still time to share
Throughout the 83rd Scientific Sessions, attendees have been writing down the reasons why they are involved in diabetes research and care. Don’t forget to add your story to the board near the registration desk in the Sails Pavilion on the upper level of the convention center.
June 26, 2023
Coming up: Is Metabolic Surgery or Lifestyle/Medical Management of Type 2 Diabetes Optimal for Long-Term Health? Long-Term Outcomes of the ARMMS-T2D Randomized Trial after 7-12 Years of Follow-Up
In a symposium beginning Monday at 3:15 p.m. PT in Ballroom 6A-B, principal Investigator John Kirwan, MSc, PhD, will present ARMMS-T2D study results comparing surgery versus medical and lifestyle intervention in patients with type 2 diabetes, as well as long-term effects post-surgery. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Upcoming presentation: Beyond Antihyperglycemic and Antihypertensive Agents for Diabetic Kidney Disease
Presenters Christine P. Limonte, MD, and Ashish Verma, MBBS, share insight into a symposium that begins Monday at 3:15 p.m. PT in Room 28. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
This afternoon: Doc, Is My GLP-1 Med Making My Sight Worse? New Considerations in Management of Diabetic Retinopathy
During a symposium beginning Monday at 3:15 p.m. PT in Ballroom 20A-C, Risa Wolf, MD, will share data that suggests GLP-1 receptor agonists can worsen diabetic retinopathy. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Videos
June 26, 2023
ADA TV: President of Medicine & Science Rodica Busui, MD, PhD
Rodica Busui, MD, PhD, discusses her role as ADA President of Medicine & Science. Dr. Busui is also the recipient of the 2023 Banting Medal for Leadership and Service, which recognizes her outstanding leadership and service to the American Diabetes Association ® .
June 26, 2023
Starting soon: Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results
A symposium beginning Monday at 1:30 p.m. PT in Ballroom 20A-C will feature Arun J. Sanyal, MD, and other investigators sharing new data on retatrutide and its effects on obesity, type 2 diabetes, and nonalcoholic steatohepatitis. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Up next: Joint ADA/ASN Symposium—How Do We Address the Psychosocial Determinants of Health in Diabetes and Kidney Disease?
During a panel discussion beginning Monday at 1:30 p.m. PT in Room 28, nephrology and diabetes experts, including Titilayo O. Ilori, MD, MSc, will discuss the impact of race, ethnicity, and underrepresentation of vulnerable populations in clinical trials in relation to diabetes and kidney disease. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Don’t miss: COORDINATE—Diabetes Study Results Symposium
In a symposium beginning Monday at 1:30 p.m. PT in Room 30, investigators including Neha Pagidipati, MD, MPH, will review the results of the COORDINATE-Diabetes trial. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Upcoming presentation: Let’s Talk about Sex (Differences in Islet Biology)
Presenter Elizabeth J. Rideout, PhD, shares insight into a symposium that begins Monday at 1:30 p.m. PT in Ballroom 6A-B. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Videos
June 26, 2023
ADA TV: Outstanding Scientific Achievement Award Recipient Carmella Evans-Molina, MD, PhD
Carmella Evans-Molina, MD, PhD, discusses the work that led her to be named the recipient of the ADA’s 2023 Outstanding Scientific Achievement Award. She delivered an award lecture Monday morning, and a recording can be viewed on the virtual platform at ADA2023.org.
#ADA2023 Social Scene
June 26, 2023
June 26, 2023
Coming up: Cultivating Provider Resiliency and Preventing Burnout
During a professional development session beginning Monday at 11:30 a.m. PT in Ballroom 20A-C, Marie Brown, MD, of the American Medical Association will explain how to effectively address clinical burnout at an organizational level using real-world examples of success centered on practice efficiency. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Upcoming presentation: Strategies to Improve the Use of SGLT2 Inhibitors and GLP-1RAs in Primary Care
Presenter Joanna Mitri, MD, MS, shares insight into a professional interest group discussion that begins Monday at 11:30 a.m. PT in Ballroom 6A-B. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Videos
June 26, 2023
ADA TV: Monday highlights at the 83rd Scientific Sessions
Scientific Sessions Meeting Planning Committee Chair Alice Y.Y. Cheng, MD, FRCPC, previews noteworthy sessions on Monday’s schedule, plus Ania M. Jastreboff, MD, PhD, and Jennifer B. Green, MD, offer sneak peeks at Monday afternoon symposia that will feature results from clinical trials.
#ADA2023 Live Coverage
June 26, 2023
Last day to save big on ADA books and merchandise
Visit the Shop Diabetes Store in the Sails Pavilion in the upper level of the convention center until 4:30 p.m. PT Monday to purchase official American Diabetes Association ® apparel, gifts, and professional books. Each sale supports diabetes research, advocacy, and educational programs.
#ADA2023 Live Coverage
June 26, 2023
Carmella Evans-Molina, MD, PhD, receives 2023 Outstanding Scientific Achievement Award
Carmella Evans-Molina, MD, PhD, is the recipient of the 2023 Outstanding Scientific Achievement Award. The award honors research in diabetes that demonstrates particular independence of thought and originality. Dr. Evans-Molina will deliver the Outstanding Scientific Achievement Award Lecture on Monday at 10:15 a.m. PT in Halls GH. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
#ADA2023 Live Coverage
June 26, 2023
Explore the Poster Hall before it closes
Don’t miss your chance to check out more than 1,400 posters featuring the latest research findings. The 83rd Scientific Sessions Poster Hall is open until 2:00 p.m. PT Monday. Poster presenters will be available for discussion during the final General Poster Session from 11:30 a.m. to 12:30 p.m. PT.
#ADA2023 Live Coverage
June 26, 2023
Don’t forget to visit the Exhibit Hall
Stop by the ground level of the convention center before 2:00 p.m. PT Monday to see the latest products and services from exhibiting companies at this year’s Scientific Sessions.
#ADA2023 Live Coverage
June 26, 2023
Mark A. Atkinson, PhD, receives 2023 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Mark A. Atkinson, PhD, is the recipient of the 2023 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes. The award honors individuals who have demonstrated outstanding research, evaluation, and care in diabetes performed from an international perspective with an international impact. Dr. Atkinson will be recognized during the National Scientific & Health Care Achievement Awards Presentation on Monday at 9:45 a.m. PT in Halls GH. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Starting soon: SGLT2i and GLP-1RA in Cardiovascular Disease—An Update for Clinical Practice in 2023
In a symposium beginning Monday at 8:00 a.m. PT in Room 28, Darren K. McGuire, MD, MHSc, will review sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists as part of an expert panel. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
June 26, 2023
Upcoming presentation: Major Advances and Discoveries in Diabetes—The Year in Review
Presenter Anath Shalev, MD, shares insight into a symposium that begins Monday at 8:00 a.m. PT in Ballroom 20A-C. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Session Coverage
June 25, 2023
ADA President of Medicine & Science shares her journey in diabetes research
Rodica Busui, MD, PhD, American Diabetes Association ® President of Medicine & Science, recalled her earliest days of working in a clinic in Romania, her fellowship at the University of Michigan, and choosing diabetes as her life’s work. She also discussed the new clinical research program in diabetes she was asked to develop.